Immunis - About the company
Immunis is a series A company based in Irvine (United States), founded in 2018. It operates as a Developer of cell therapies for age-related and disease-related immune deficits. Immunis has raised $67.4M in funding from Remiges Ventures. The company has 151 active competitors, including 45 funded and 17 that have exited. Its top competitors include companies like Retro, Eupraxia Pharmaceuticals and TissueGene.
Company Details
Developer of cell therapies for age-related and disease-related immune deficits. It offers a STEM product line developed from human stem cells that secrete immune modulators for treating muscle atrophy in patients with knee osteoarthritis and muscle performance in seniors with obesity and muscle weakness.
- Website
- immunisbiomedical.com/home/
- Email ID
- *****@immunisbiomedical.com
Key Metrics
Founded Year
2018
Location
Irvine, United States
Stage
Series A
Total Funding
$67.4M in 4 rounds
Latest Funding Round
Investors
Ranked
6th among 151 active competitors
Employee Count
24 as on Sep 30, 2026
Legal entities associated with Immunis
Immunis is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Immunis, Inc. CIN: 83-2267332 , United States, Active | Dec 31, 2017 | - | 3 (As on Dec 31, 2021) | - |
Sign up to download Immunis' company profile
Immunis's funding and investors
Immunis has raised a total funding of $67.4M over 4 rounds. Its first funding round was on Aug 04, 2022. Immunis has 6 institutional investors.
Here is the list of recent funding rounds of Immunis:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 28, 2026 | 6842008 | Series A | 6085110 | 7206912 | 5516629 | 4296635 |
Jan 11, 2025 | 7368416 | Series A | 8247675 | 4683910 | 5753723 | |
Jun 17, 2024 | 3450886 | Series A | 1978558 | 3710752 | 6058008 | 9089702 |
View details of Immunis's funding rounds and investors
Immunis' founders and board of directors
Founder? Claim ProfileImmunis' employee count trend
Immunis has 24 employees as of Sep 26. Here is Immunis's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immunis's Competitors and alternates
Top competitors of Immunis include Retro, Eupraxia Pharmaceuticals and TissueGene. Here is the list of Top 10 competitors of Immunis, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Retro 2020, Redwood City (United States), Series D | Developer of therapeutics targeting cellular mechanisms to treat aging diseases | $180M | - | 65/100 |
2nd | Eupraxia Pharmaceuticals 2012, Vancouver (Canada), Public | Sustained released formulation for osteoarthritis | $2.44M | 62/100 | |
3rd | TissueGene 1999, Rockville (United States), Series C | Developer of regenerative therapies for orthopedic diseases | $94.6M | 58/100 | |
4th | Remedium Bio 2020, Needham (United States), Series A | Developer of gene therapies for a broad range of diseases | $15M | 57/100 | |
5th | Levicept 2012, Sandwich (United Kingdom), Series B | Developer of therapeutics for the treatment of chronic pain | $50.9M | 56/100 | |
6th | Immunis 2018, Irvine (United States), Series A | Developer of cell therapies for age-related and disease-related immune deficits | $67.4M | 56/100 | |
7th | Ensoma 2019, Boston (United States), Series B | Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 54/100 | |
8th | RenewalBio 2022, Rehovot (Israel), Seed | Developer of a synthetic embryo and stem-cell therapeutic platform | - | 52/100 | |
9th | ZEO ScientifiX 2011, Fort Lauderdale (United States), Seed | Biopharmaceutical company focused on researching novel biological therapeutics | $1M | - | 52/100 |
10th | Athersys 1995, Cleveland (United States), Public | Stem Cell Therapy for the treatment of cardiovascular disease areas | $74.4M | 52/100 |
Looking for more details on Immunis's competitors? Click here to see the top ones
Immunis's Investments and acquisitions
Immunis has made no investments or acquisitions yet.
Reports related to Immunis
Here is the latest report on Immunis's sector:
News related to Immunis
Media has covered Immunis for a total of 3 events in the last 1 year, 2 of them have been about company updates.
•
Immunis Named Semifinalist in National Academy of Medicine’s $1.5 Million Healthy Longevity Global Competition Grand PrizeBusiness Wire•Oct 13, 2026•Immunis
•
•
•
Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology ReportBusiness Wire•Aug 14, 2025•Immunis
•
Immunis Closes $25 Million Series A-1 Financing RoundYahoo•Jan 11, 2025•Immunis, Remiges Ventures, Continuum Health Ventures, Bold Capital Partners and 2 others
•
Immunis Successfully Completes its Phase 1/2a Clinical Trial Targeting Muscle AtrophyBusiness Wire•Nov 19, 2024•Immunis
•
FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity TrialBusiness Wire•Sep 10, 2024•Immunis
•
Immunis to use MRI-based AI muscle analysis for sarcopenia trialhttps://www.clinicaltrialsarena.com/•Jul 26, 2024•Immunis
•
Immunis Partners With Springbok Analytics To Assess Clinical Efficacy Of Immuna In Reversing SarcopeniaBusiness Wire•Jul 25, 2024•Immunis, Springbok Analytics
•
Immunis has filed a notice of an exempt offering of securities to raise $20,000,000.00 in New Equity Investment.https://www.intelligence360.news/•Jul 16, 2024•Immunis
Are you a Founder ?
FAQs about Immunis
Explore our recently published companies
- Tibnology - India based, Unfunded company
- SS Concrete Coatings - Freeport based, Unfunded company
- S K Reality - Pune based, Unfunded company
- Roemo Fliesen - Germany based, 1991 founded, Unfunded company
- Rocky Mountain Trades - Logan based, Unfunded company
- Roberta Flanagan Realtor - Merced based, 1960 founded, Unfunded company
